Is Regular Probiotic Practice Safe for Management of Sepsis?

Your Location：

Home >

Browse articles >

Is Regular Probiotic Practice Safe for Management of Sepsis?

Review | Updated：2022-02-22

|

- Is Regular Probiotic Practice Safe for Management of Sepsis?
- Is Regular Probiotic Practice Safe for Management of Sepsis?
- Chinese Journal of Integrative Medicine 2022年28卷第2期页码：185-192
- Affiliations：
  
  1.Department of Pharmacology, ISF College of Pharmacy,Moga (Punjab), India
  2.Department of Pharmacology, Amity Institute of Pharmacy, Amity University, Lucknow (UP), India
- Author bio：
  
  Dr. Alok Shiomurti Tripathi, E-mail:astripathi@lko.amity.edu
- Funds：
- DOI：10.1007/s11655-021-3334-5
  中图分类号：
- 纸质出版日期：2022-02-01，
  
  网络出版日期：2021-07-16，
  
  录用日期：2020-09-28
Scan for full text
Rishabh Kumar, Alok Shiomurti Tripathi, Nidhi Sharma, 等. Is Regular Probiotic Practice Safe for Management of Sepsis?[J]. Chinese Journal of Integrative Medicine, 2022,28(2):185-192.

Rishabh Kumar, Alok Shiomurti Tripathi, Nidhi Sharma, et al. Is Regular Probiotic Practice Safe for Management of Sepsis?[J]. Chinese Journal of Integrative Medicine, 2022,28(2):185-192.
Rishabh Kumar, Alok Shiomurti Tripathi, Nidhi Sharma, 等. Is Regular Probiotic Practice Safe for Management of Sepsis?[J]. Chinese Journal of Integrative Medicine, 2022,28(2):185-192. DOI： 10.1007/s11655-021-3334-5.

Rishabh Kumar, Alok Shiomurti Tripathi, Nidhi Sharma, et al. Is Regular Probiotic Practice Safe for Management of Sepsis?[J]. Chinese Journal of Integrative Medicine, 2022,28(2):185-192. DOI： 10.1007/s11655-021-3334-5.

摘要

几十年来

肠道一直被认为在脓毒症的发病机制中发挥重要作用. 在大多数重症监护病房的患者中

脓毒症是一种由机体免疫反应失调引起的严重威胁生命的慢性感染疾病. 益生菌在脓毒症治疗中具有双重作用: 益生菌在许多情况下可引起脓毒症

并可能影响预后. 临床前和临床研究表明

益生菌治疗可改善脓毒症中各种炎症介质

如肿瘤坏死因子、白细胞介素-10 (IL-10)、IL-6等. 此外

益生菌也被发现可以减少与肠易激疾病相关的病理状况的严重程度

并预防脓毒症时发生心内膜炎. 相反

对于新生儿和无胸腺的成年小鼠

益生菌治疗对死亡和脓毒症引起的炎症并无任何有益的影响. 重要的是

很少的临床试验发现益生菌是通过促进炎症级联而非抑制它致使脓毒症恶化. 本综述讨论了有关益生菌治疗脓毒症有益或有害影响的各种研究.

Abstract

For decades

the gut has been thought to play an important role in sepsis pathogenesis. Sepsis is a serious life-threatening

chronic condition of an infection caused by dysregulated host immune response in most of the intensive care unit patients. Probiotics have dual roles in polymicrobial sepsis i.e. probiotics may induce sepsis in many cases and may prevent its prognosis in many cases. Experimental evidence from both pre-clinical and clinical studies have demonstrated that probiotic therapy ameliorates various inflammatory mediators such as tumor necrosis factor

interleukin-10 (IL-10)

IL-6

etc.

in septicemia. In addition

probiotic use was also found to reduce the severity of pathological conditions associated with irritable bowel disorder and prevent development of endocarditis in septicemia. On contrary

probiotic therapy in neonatal and athymic adult mice fail to provide any beneficial effects on mortality and sepsis-induced inflammation. Importantly

in few clinical trials probiotic use was found to aggravate sepsis by promoting inflammatory cascade rather than suppressing it. This review discusses various studies regarding the beneficial or harmful effects associated with probiotic therapy in sepsis.

关键词

Keywords

sepsisprobioticsmicrobial floraimmune system

references

Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016;164:337-340.

Sekirov I, Russell SL, Antunes LCM, et al. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904.

FAO/WHO (2001): Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Available at http://www.fao.org/publications/card/en/c/7c102d95-2fd5-5b22-8faf-f0b2e68dfbb6/http://www.fao.org/publications/card/en/c/7c102d95-2fd5-5b22-8faf-f0b2e68dfbb6/

Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.

Haak BW, Wiersinga WJ. The role of the gut microbiota in sepsis. Lancet Gastroenterol Hepatol 2017;2:135-143.

Mira JC, Gentile LF, Mathias BJ, et al. Sepsis pathophysiology, chronic critical illness and PICS. Crit Care Med 2017;45:253.

Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis.Current estimates and limitations. Am J Respir Crit Care 2016;193:259-272.

Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS:a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580-588.

Reinhart K, Daniels R, Kissoon N, et al. Recognizing sepsis as a global health priority a WHO resolution. N Engl J Med 2017;377:414-417.

Chung HO, Rochwer B, Fox-Robichaud AE. The treatment of sepsis: from failed therapies to new possibilities. Vasc Responses Pathog 2016;221-231.

Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol 2018;14:121-137.

Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304-377.

Haak BW, Prescott HC, Wiersinga WJ. Therapeutic potential of the gut microbiota in the prevention and treatment of sepsis. Front Immunol 2018;9:2042.

Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-438.

Harris VC, Haak BW, Boele van Hensbroek M, et al. The intestinal microbiome in infectious diseases: the clinical relevance of a rapidly emerging field. Open Forum Infect Dis 2017;4:ofx144.

Kim S, Covington A, Pamer EG. The intestinal microbiota:antibiotics, colonization resistance, and enteric pathogens.Immunol Rev 2017;279:90-105.

Schirmer M, Smeekens SP, Vlamakis H, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 2016;167:1125-1136.

Schuijt TJ, van der Poll T, de Vos WM, et al. The intestinal microbiota and host immune interactions in the critically ill.Trends Microbiol 2013;21:221-229.

Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis.Nat Rev Microbiol 2017;15:55-63.

He Y, Wen Q, Yao F, et al. Gut-lung axis: the microbial contributions and clinical implications. Crit Rev Microbiol 2017;43:81-95.

Schuijt TJ, Lankelma JM, Scicluna BP, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 2016;65:575-583.

Isolauri E, Salminen S, Ouwehand AC. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 2004;18:299-313.

Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014;14:141-153.

Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut microbes 2012;3:4-14.

Kwon HK, Lee CG, So JS, et al. Generation of regulatory dendritic cells and CD4+ Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A 2010;107:2159-2164.

Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8:411.

Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013;13:321-335.

Naidu AS, Bidlack WR, Clemens RA. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr 1999;39:13-126.

Yan F, Polk DB. Probiotics: progress toward novel therapies for intestinal diseases. Curr Opin Gastroenterol 2010;26:95-101.

Wischmeyer PE, McDonald D, Knight R. Role of the microbiome, probiotics, and 'dysbiosis therapy' in critical illness. Curr Opin Crit Care 2016;22:347-353.

Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis 2013;13:1057-1098.

Hodzic Z, Bolock AM, Good M. The role of mucosal immunity in the pathogenesis of necrotizing enterocolitis.Front Pediatr 2017;5:40.

Arboleya S, Stanton C, Ryan CA, et al. Bosom buddies: the symbiotic relationship between infants and Bifidobacterium longum ssp. longum and ssp. infantis. Genetic and probiotic features. Annu Rev Food Sci Technol 2016;7:1-21.

Tojo R, Suárez A, Clemente MG, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 2014;20:15163.

Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J 2004;80:516-526.

Ng SC, Hart AL, Kamm MA, et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2008;15:300-310.

Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol 2013;34:129-136.

Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care 2010;182:1047-1057.

Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007;115:1-11.

Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009;136:2015-2031.

Boller T, Felix G. A renaissance of elicitors: perception of microbe-associated molecular patterns and danger signals by pattern-recognition receptors. Annu Rev Plant Biol 2009;60:379-406.

Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-643.

Celiberto LS, Graef FA, Healey GR, et al. Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome. J Immunol Clin Res 2018;155:36-52.

Norman K, Pichard C, Lochs H, et al. Prognostic impact of disease-related malnutrition. Clin Nutr 2008;27:5-15.

Burchardi H, Schneider H. Economic aspects of severe sepsis. Pharmacoeconomics 2004;22:793-813.

Fijan S. Microorganisms with claimed probiotic properties:an overview of recent literature. Int J Environ Res Public Health 2014;11:4745-4767.

Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010;7:503-514.

Sánchez B, Delgado S, Blanco-Míguez A, et al. Probiotics,gut microbiota, and their influence on host health and disease. Mol Nutr Food Res 2017;61:160-240.

Sikorska H, Smoragiewicz W. Role of probiotics in the prevention and treatment of methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents 2013;42:475-481.

Khailova L, Frank DN, Dominguez JA, et al. Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis.Anesthesiology 2013;119:166-177.

Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-1633.

Dani C, Biadaioli R, Bertini G, et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants: a prospective double-blind study. Neonatology 2002;82:103-108.

Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. Am J Perinatol 2011;31:63-69.

Deshpande G, Rao S, Patole S, et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010;125:921-930.

Siro I, Kápolna E, Kápolna B, et al. Functional food. Product development, marketing and consumer acceptance—A review. Appetite 2008;51:456-467.

Franz CM, Stiles ME, Schleifer KH, et al. Enterococci in foods—a conundrum for food safety. Int J Food Microbiol 2003;88:105-122.

Liu Y, Tran DQ, Fatheree NY, et al. Lactobacillus reuteri DSM 17938 differentially modulates effector memory T cells and Foxp3+ regulatory T cells in a mouse model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2014;307:G177-G186.

Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006;83:1256-1264.

Foberg U, Frydén A, Kihlström E, et al. Yersinia enterocolitica septicemia: clinical and microbiological aspects. Scand J Infect Dis 1986;18:269-279.

Besselink MG, van Santvoort HC, Buskens E, et al.Probiotic prophylaxis in predicted severe acute pancreatitis:a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:651-659.

Manzanares W, Lemieux M, Langlois PL, et al. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care 2016;20:262.

Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome.J Pediatr Gastroenterol Nutr 2004;38:457-458.

Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. J Microbiol 1996;70:347-358.

Jafarnejad S, Shab Bidar S, Speakman JR, et al. Probiotics reduce the risk of antibiotic associated diarrhea in adults(18–64 years) but not the elderly (> 65 years): a meta analysis. Nutr Clin Pract 2016;31:502-513.

Adawi D, Ahrné S, Molin G. Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model.Int J Food Microbiol 2001;70:213-220.

Reid G, Jass J, Sebulsky MT, et al. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003;16:658-672.

Gueimonde M, Sánchez B, de los Reyes-Gavilán CG, et al.Antibiotic resistance in probiotic bacteria. Front Microbiol 2013;4:202.

Ammor MS, Flórez AB, Mayo B. Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria.Food Microbiol 2007;24:559-570.

Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 2007;10:729-734.

More>

0

浏览量

0

Downloads

0

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

相关文章

Fangji Fuling Decoction Alleviates Sepsis by Blocking MAPK14/FOXO3A Signaling Pathway

Mechanism of Shengmai Injection on Anti-Sepsis and Protective Activities of Intestinal Mucosal Barrier in Mice

相关作者

暂无数据

相关机构

Department of Critical Care Medicine, Changzhou Hospital of Traditional of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

Department of Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College

⁰